The SEPTIN6 Knockout Ramos Cell Line is a CRISPR/Cas9-edited human B-lymphocyte knockout cell line engineered to disrupt the SEPTIN6 gene in the Ramos background. This product provides a stable loss-of-function model for investigating septin biology in a lymphoid cellular context. By leveraging CRISPR/Cas9-mediated gene targeting, the line offers researchers a defined genetic tool to dissect SEPTIN6-dependent cellular processes without reliance on transient suppression methods.
The host Ramos cell line is an EBV-negative, MYC translocation t(8;14)-driven Burkitt’s lymphoma model of mature B lymphocyte origin. These cells retain key features of antibody-producing immune cells and are extensively used to study humoral immunity and B-cell oncogenesis. Their rapid proliferation, aberrant cell cycle regulation, and underlying genomic instability establish a pertinent system for probing mitotic and cytoskeletal gene functions.
SEPTIN6 encodes a GTP-binding protein that assembles into heteromeric septin filaments, typically together with SEPT2 and SEPT7. These structures concentrate at the cleavage furrow and function as scaffolds that coordinate actomyosin ring contraction and membrane abscission during cytokinesis. Mechanistically, SEPTIN6 interacts with anillin, myosin II, and components of the exocyst complex such as EXOC4/Sec8. Its activity is regulated by upstream kinases including CDK1, Aurora B kinase, and PLK1, and it operates within pathways involving CDC42, RHO, ROCK, and citron kinase. Through these interactions, SEPTIN6 helps maintain genomic stability by ensuring faithful completion of cell division.
Disruption of SEPTIN6 in the Ramos B-cell lymphoma context provides a powerful model to examine how cytokinesis failure contributes to malignant progression. Given the MYC-driven proliferative pressure and inherent chromosomal instability of this cell line, loss of SEPTIN6-mediated cytokinetic coordination may exacerbate aneuploidy and influence therapeutic responses. The knockout line thus enables dissection of septin-dependent tumor-suppressive or oncogenic mechanisms in B-cell malignancies and facilitates assessment of drug sensitivity, such as to Aurora kinase inhibitors.
Typical research applications include investigation of cytokinesis defects in lymphoma, characterization of septin scaffold functions during B-cell division, screening for synthetic lethal interactions, and evaluation of chemotherapeutic sensitivity in Burkitt’s lymphoma models. The line is validated for use in Western blotting of septin complex and cell cycle markers, flow cytometric cell cycle analysis with propidium iodide staining, immunofluorescence microscopy for septin localization, time-lapse imaging of cell division, MTS viability assays, Annexin V apoptosis assays, and drug sensitivity panels. For additional information or to request a quote, please contact Ascent Research.
